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updating systematic reviews
Nadera Ahmadzai1*, Sydne J Newberry2, Margaret A Maglione2, Alexander Tsertsvadze1, Mohammed T Ansari1,
Susanne Hempel2, Aneesa Motala2, Sophia Tsouros1, Jennifer J Schneider Chafen3, Roberta Shanman2,
David Moher1 and Paul G Shekelle2,4Abstract
Background: Systematic reviews (SRs) can become outdated as new evidence emerges over time. Organizations
that produce SRs need a surveillance method to determine when reviews are likely to require updating. This report
describes the development and initial results of a surveillance system to assess SRs produced by the Agency for
Healthcare Research and Quality (AHRQ) Evidence-based Practice Center (EPC) Program.
Methods: Twenty-four SRs were assessed using existing methods that incorporate limited literature searches, expert
opinion, and quantitative methods for the presence of signals triggering the need for updating. The system was
designed to begin surveillance six months after the release of the original review, and thenceforth every six months
for any review not classified as being a high priority for updating. The outcome of each round of surveillance was a
classification of the SR as being low, medium or high priority for updating.
Results: Twenty-four SRs underwent surveillance at least once, and ten underwent surveillance a second time
during the 18 months of the program. Two SRs were classified as high, five as medium, and 17 as low priority for
updating. The time lapse between the searches conducted for the original reports and the updated searches
(search time lapse - STL) ranged from 11 months to 62 months: The STL for the high priority reports were 29 months
and 54 months; those for medium priority reports ranged from 19 to 62 months; and those for low priority reports
ranged from 11 to 33 months. Neither the STL nor the number of new relevant articles was perfectly associated
with a signal for updating. Challenges of implementing the surveillance system included determining what
constituted the actual conclusions of an SR that required assessing; and sometimes poor response rates of experts.
Conclusion: In this system of regular surveillance of 24 systematic reviews on a variety of clinical interventions
produced by a leading organization, about 70% of reviews were determined to have a low priority for updating.
Evidence suggests that the time period for surveillance is yearly rather than the six months used in this project.
Keywords: Systematic review, Updating, SurveillanceBackground
Systematic reviews (SRs) on the effectiveness and safety
of various health interventions are the basis for clinical
practice guidelines, public and corporate policy, and
clinical and consumer decision-making. These SRs pro-
vide systematically searched, collected, evaluated, and
synthesized scientific evidence to objectively compare* Correspondence: nahmadzai@ohri.ca
1Knowledge Synthesis Group, Ottawa Hospital Research Institute, Clinical
Epidemiology Program, Center for Practice-Changing Research, 501 Smyth
Road, Ottawa, ON K1H 8L6, Canada
Full list of author information is available at the end of the article
© 2013 Ahmadzai et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe effectiveness, benefits, and safety of different health
interventions. The production of SRs is based on stan-
dardized, structured, and explicit methodological guid-
ance. The SRs endeavor to focus on patient-relevant
outcomes (for example, mortality, pain, quality of life,
functional status, myocardial infarction) in addition to
relevant intermediate surrogate outcome measures (for
example, cholesterol levels, serum glucose levels, red
blood cell count) [1].
Systematic reviews may be conducted by independent
groups of researchers or by researchers associated with
large organizations such as the Cochrane Collaboration;ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and Quality (AHRQ), which administers a group of
Evidence-based Practice Centers (EPC) throughout North
America; and the National Institute for Health and
Clinical Excellence (NICE) in the UK [2]. A primary re-
sponsibility of these organizations is the conduct of sys-
tematic reviews, the results of which are often posted
on their websites.
The inevitable - and rapid - accumulation of new re-
search findings has raised concern among these organiza-
tions about how best to identify which reviews may be out
of date and whether to sponsor an update or simply re-
move the outdated review from their websites. To date,
organizations and initiatives (for example, Cochrane
Collaboration, Drug Effectiveness Review Project (DERP))
have relied on time-based (for example, annual, biennial)
periodic updating policies that have proven to be prob-
lematic in terms of feasibility and efficiency [3-5]. How-
ever several lines of evidence demonstrate that reviews
become obsolete at different rates, suggesting that a sys-
tem of regular surveillance might be a more effective way
of identifying potentially out-of-date reviews. In 2006, the
DERP implemented a strategy for assessing the need for
updating systematic reviews of comparative effectiveness
and safety of drug interventions evaluated in controlled
clinical trials [6]. The DERP’s stakeholders need to make
coverage decisions for new drugs, and therefore the ap-
pearance of a new drug is a strong signal for an update.
However, not all SR users (for example guideline devel-
opers) might consider a new drug within an established
class (such as a new statin or angiotensin receptor antag-
onist) as an indication of the need for an update. Further-
more, SRs may deal with non-pharmacologic interventions
(for example, diagnostic screening) and include observa-
tional studies.
AHRQ supported a pilot study comparing different
methods to assess signals for the need to update SRs
and another study to assess an initial set of SRs that
were considered Comparative Effectiveness Reviews
(CERs) for the need to update. CERs are systematic re-
views that aim to compare the benefit and harms of a
range of options rather than only answering a narrow
question on safety and effectiveness of a single therapy
[2]. Based on these pilot studies, AHRQ supported the
development of a surveillance system for regularly moni-
toring AHRQ’s portfolio of SRs. This article presents the
results of the surveillance system covering June 2011 to
November 2012.
Methods
The surveillance system - summary overview
Two EPCs (RAND, University of Ottawa) participated in
the development of the surveillance system; a third EPC
(ECRI) assisted in obtaining safety alerts). The RANDand Ottawa EPCs had independently developed methods
to assess SRs for the need to update [7,8]; a formal com-
parison of the two showed they produced similar results
[9]. In developing and implementing the surveillance
system, we operationalized a proposal made in our earl-
ier CER surveillance report for what such a system
would look like (see Figure 1). This article describes the
surveillance assessment of 24 consecutive SRs conducted
for the AHRQ Effective Health Care’s Comparative
Effectiveness Review program [10-33].
The surveillance system was designed to conduct an
assessment of a SR six months after its release and every
six months thereafter until the assessment identified
signals sufficient to classify it as ‘high priority’ for an up-
date. Briefly, six months after release of a SR, we conduct
abbreviated literature searches, using the strategy
employed in the original SR, but limited to five general
medicine journals and approximately five specialty jour-
nals specific to the topic of the SR and, with a few excep-
tions. Newly identified evidence relevant to the key
questions and the original conclusions was abstracted, and
pre-specified criteria were used to detect the presence of
qualitative and/or quantitative signals for updating (EPC
SRs are organized around a set of key questions, each of
which might have multiple parts, resulting in the need for
multiple conclusions) [7]. The method also incorporates
expert opinion regarding the validity or currency of con-
clusions reached in the SR and government safety alerts
relevant to the SR [8]. Based on a combination of the
weight of the evidence, signals, and expert opinion, a de-
termination was made regarding the need to update each
conclusion for each key question, with the expectation
that a change in conclusion may yield a change in clinical
practice. That is, each key question (KQ)-specific conclu-
sion within a SR was categorized as up-to-date, possibly
out-of-date, probably out-of-date, or out-of-date [8]. Fi-
nally, based on: 1) the proportion of key questions whose
conclusions were determined to require updating or the
urgency to update a particular set of conclusions, and 2)
the extent of outdatedness, a global assessment of priority
status was assigned to updating the full report (high,
medium, or low), and the results of the process were sum-
marized in a brief report. SRs assigned a low or medium
priority for updating were re-assessed six months later.
Reports assigned a high priority for updating were not re-
assessed. The decision to update or withdraw the report is
made by AHRQ, who consider the availability of resources
and other factors when making a final decision. Detailed
methods of the surveillance process are presented as the
following:
Abbreviated search, study selection, and data extraction
The ascertainment of updating signals relied on qualita-
tive and/or quantitative criteria developed originally for
Detected 
Signals
Safety alerts Expert Opinion
Results
Original Systematic Review 
Conducting update search using the
original SR search strategy
Exporting the identified articles to a  
reference managerdatabase
Screening title and 
abstract
Screening full text
Number of 
included studies
Number of 
excluded studies
Identifying qualitative and/or quantitative signals 
updating
Number of 
excluded studies
Number of 
included studies
Extracting data
Deciding on updating status of 
Systematic Review
AHRQ 
committee to 
make final 
decision
Low priority 
for updating
Medium priority 
for updating
High priority for 
updating
Goes to next cycle assessment 6 
months later
ECRI 
surveillance
Contacting 
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Figure 1 The process of surveillance assessment for a systematic review (SR). Figure 1 portrays the overall process of surveillance
assessment for an SR that mainly includes: 1) literature search, 2) contacting experts, and 3) obtaining safety alerts from various sources sent by
ECRI (one of the AHRQ evidence-based centers). The number of hits identified by literature search would be transferred to Reference Manager
database and then will be screened by: 1) title and abstract, and 2) full text. The data was extracted from the number of studies that were
deemed eligible for inclusion. Next, the extracted data was assessed for identifying qualitative and quantitative signals. Then, the findings from
literature, expert opinion, and safety alerts were collated and assessed for updating priority status (high, medium or low). If an SR was
deemed as ‘high’ priority for assessment, it was referred to AHRQ for updating. If an SR was deemed as ‘medium’ or ‘high’ priority for updating, it
was re-assessed six months after the completion of the first assessment.
Ahmadzai et al. Systematic Reviews 2013, 2:104 Page 3 of 16
http://www.systematicreviewsjournal.com/content/2/1/104the Ottawa method [7] and expert opinion as used in the
RAND method [8]. For each SR, we conducted an abbre-
viated update search as described in previous publications
[7,9,34]. We employed the strategies used in the original
published SRs but limited the sources searched to five
general medical journals (Annals of Internal Medicine,
BMJ, JAMA, The Lancet, and New England Journal ofMedicine) and approximately five topic-specific specialty
journals (usually the journals that contributed the most
evidence to the original report; (if a particular specialty
journal was not catalogued in PubMed, we would search
the more relevant database as well). These searches were
conducted for a time period starting six months prior to
the last date covered by the searches for the original SR
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to delayed publication) up to the present. We also
assessed the eligibility of studies referenced by content ex-
perts (further detail on the experts in the following sec-
tions). After removing duplicates from identified records,
one reviewer used the inclusion/exclusion criteria speci-
fied in the original SR to screen titles and abstracts and
then full texts of potentially relevant records. For each in-
cluded new study, one reviewer extracted relevant data on
study characteristics (for example, design, sample size,
follow-up duration), demographic factors for study partici-
pants (for example, age, sex, condition), treatment (for ex-
ample, type, frequency, dose), outcome characteristics,
and results into an evidence table.
Ascertainment of updating signals
To identify signals/triggers for updating, we applied quali-
tative and/or quantitative criteria [7] to the abstracted evi-
dence for each conclusion in the original SR. For each
conclusion, we first documented the absence of new evi-
dence (that is, no new evidence or new evidence showing
the same or similar conclusion as the original SR) or the
presence of new evidence meeting the pre-defined criteria
of signal(s) indicating a need for updating (Table 1).
We then assessed whether new evidence provided or
contributed to a qualitative or quantitative signal. One
example of a qualitative signal might include finding a
newly published pivotal trial with results opposite to that
of the original SR with respect to an efficacy outcome
(for example, effective versus ineffective or vice versa) or
a harm (for example, a newly identified risk of harm that
outweighs the previously observed benefits). The original
definition of a pivotal trial was one published in one of
the top five general medical journals or a trial whose
sample size was at least triple that of the largest trial in
the original SR [7]. For this application we made some
adaptations to account for key questions for which ob-
servational studies were the study design of choice;
namely we did not require new large cohort studies to
have at least three times the number of participants as
existing large cohorts. Other examples of qualitative sig-
nals included a superior new treatment (for example, a
new treatment significantly more effective than one
assessed in the SR); or a new population subgroup (that
is, the treatment assessed in the SR has subsequently
been tested on a new population). In contrast, new evi-
dence generates a quantitative signal if its incorporation
into a SR’s original meta-analysis changes a statistically
non-significant pooled estimate into a statistically signifi-
cant one or vice versa [7].
Clinical content experts
We identified and contacted two sets of clinical experts:
a) those who had worked on the SR in question (forexample, the project lead, clinical lead, members of the
technical expert panel, and peer reviewers) and b) other
clinical experts in the clinical content area who had not
worked on the SR in question (for example, local or ex-
ternal subject matter experts). For each SR, we created a
matrix that included each of the original key questions
and a summary of each conclusion in the original report.
Respondents were asked to provide their opinions on
whether or not each conclusion was still valid. They
were also asked to provide reference citations for any
new studies they were aware of that might invalidate or
otherwise alter the conclusion(s) as well as studies that
were pertinent to the topic but might not address a par-
ticular conclusion directly (for example, studies of newer
treatments that may have rendered the original treat-
ments out-of-date). The responding experts were offered
a small honorarium; reminders were sent to experts who
did not initially respond.
Safety alerts
We examined safety and adverse event alerts relevant to
each SR. This information was collected from Med-
Watch, the US Food and Drug Administration’s Safety
Information and Adverse Event reporting system; the
UK’s Medicines and Health Care Products Regulatory
Agency (MHRA); and Health Canada.
Determination of updating status for SRs
The information on updating signals, expert opinion,
and safety alerts was collated, summarized, and tabu-
lated. Taking into consideration the totality of evidence,
we used a set of decision rules/guidance originally used
in the pilot studies [8,9] to characterize any given KQ-
related conclusion(s) as up-to-date, possibly out-of-date,
probably out-of-date, or out-of- date. Based on the total-
ity of these characterizations, each SR was assigned to
high, medium, or low updating priority groups. The de-
cision to assign a high priority was not based strictly on
the proportion of conclusions determined to be probably
or definitely out-of-date, but rather, was a global judg-
ment informed by a set of guidelines; for example, one
out-of-date conclusion that could result in harm or in-
ferior treatment could give rise to a high priority for up-
dating. The criteria for determining updating status are
provided in Additional file 1.
For each of the SRs that underwent surveillance, we
summarized our findings in a brief report. These reports
are now posted on the AHRQ website along with the
original SRs to which they refer.
Assessment of the findings across SRs
To gain a sense of how long it takes for SRs to go out-
of-date, we assessed the proportion of the SRs that went
through the surveillance process at least once that
Table 1 Criteria for determining that a conclusion is out-of-date
Ottawa’s label Ottawa method
Qualitative criteria for potentially invalidating signals
A1 Opposing findings: a pivotal* trial or systematic review (or guidelines) including at least one new trial that characterized the
treatment in terms opposite to those used earlier
A2 Substantial harm: a pivotal trial or systematic review (or guidelines) whose results called into question the use of the treatment
based on evidence of harm or that did not proscribe use entirely but did potentially affect clinical decision-making
A3 A superior new treatment: a pivotal trial or systematic review (or guidelines) whose results identified another treatment as
significantly superior to the one evaluated in the original review, based on efficacy or harm
Qualitative criteria for signals of major changes
A4 Important changes in effectiveness short of ‘opposing findings’
A5 Clinically important expansion of treatment
A6 Clinically important caveat
A7 Opposing findings from discordant meta-analysis or non-pivotal trial
Quantitative criteria signals of changes in evidence
B1 A change in statistical significance (from nonsignificant to significant)
B2 A change in relative effect size of at least 50 percent
RAND’s label RAND method indications for the need for an update
1 Original conclusion is still valid and this portion of the original report does not need updating. This conclusion was reached if we
found no new evidence or only confirmatory evidence and all responding experts assessed the CER conclusion as still valid, we
classified the CER conclusion as still valid
2 Original conclusion is possibly out-of-date and this portion of the original report may need updating. This conclusion was reached if we
found some new evidence that might change the CER conclusion, and/or a minority of responding experts assessed the CER conclusion
as having new evidence that might change the conclusion, then we classified the CER conclusion as possibly out-of-date
3 Original conclusion is probably out-of-date and this portion of the original report may need updating. This conclusion was reached if we
found substantial new evidence that might change the CER conclusion, and/or a majority of responding experts assessed the CER
conclusion as having new evidence that might change the conclusion, then we classified the CER conclusion as probably out-of-date
4 Original conclusion is out-of-date. This conclusion was reached if we found new evidence that rendered the CER conclusion out-of-
date or no longer applicable; we classified the CER conclusion as out-of-date. Recognizing that our literature searches were limited,
we reserved this category only for situations where a limited search would produce prima facie evidence that a conclusion was
out-of-date, such as the withdrawal of a drug or surgical device from the market, a black box warning from FDA, and so on
Abbreviation: CER comparative effectiveness review, FDA Food and Drug Administration.
*a pivotal trial is defined as trial that is published in one of the top five general medical journals or a trial whose sample size is at least triple that of the largest
trial in the original systematic review.
Legend: Table 1 presents the criteria used to determine if a conclusion is out of date within an SR (here CER). Criteria A1 to B2 come from the Ottawa method
and criteria 1 to 4 are based on the RAND method.
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function of the length of time since their publication
and from the date of their latest searches.
Results
Sampling of SRs for assessment
Between June 2011 and November 2012, we assessed 24
SRs at least once. When we implemented the surveillance
system, a backlog of SRs had accumulated and needed to
be assessed. In addition, there was a 3- to 17- month lag
between the completion of the original or update search
and the release of the reports. Thus, there was a time span
of 11 to 62 months from the completion of the original or
update searches and the surveillance search (Table 2).
Characteristics of SRs
The SRs varied widely in the kinds of interventions they
tested and their target populations. Interventions includedpharmaceuticals [11-14,16,17,20-23,28,31,33], surgical pro-
cedures [10,18,21,22,25,26,28], radiotherapy [19,22], non-
pharmacological procedures [24,28,30], diagnostic and
preventive interventions [27,29], and a complementary
and alternative medicine intervention [14]. The popula-
tions of interest included patients with cancer, tumors,
and anomalies on screening [10,11,19,22,25], heart disease
[18,20], cystic fibrosis [12], autism [13], trauma [15,16],
cuff tears [21], lipid therapy[17], hypertension [24], renal
diseases [26,31], attention deficit hyperactivity disorder
[33], psychiatric and behavioral conditions [32], depres-
sion [30], infection [29], pelvic pain [28], sleep apnea [27],
and preterm labor [23].
The characteristics of the 24 SRs and the correspond-
ing surveillance assessments are presented in Table 2.
Briefly, the number of key questions (the questions that
frame AHRQ SRs) across the 24 SRs ranged from three
[10,17,26,33] to seven [12,13,27], although each key
Table 2 Characteristics of 24 comparative effectiveness reviews (CERs) and their associated updating surveillance assessments
CER title; first author last name (publication date) Latest search date for
CER (across databases)
Number of included studies in
CER (total or per KQ)
Period covered by
surveillance
assessment search
Number of new
studies judged
as relevant for
inclusion in CER(Journal publication, if available) Time between search and
report release
Time between original
searches and update search
Comparative Effectiveness of Therapies for Clinically
Localized Prostate Cancer; Wilt (February 2008) [22]
September 2007 436 January 2007 to March 2012 21
(Systematic review: association Between Hospital and
Surgeon Radical Prostatectomy Volume and Patient
Outcomes: A Systematic Review) [35]
5 months 54 months
Comparative Effectiveness of Medications to Reduce
Risk of Primary Breast Cancer in Women; Nelson
(September 2009) [11]
January 2009 13 (KQ1,KQ3) January 2008 to July 2011 3
(Systematic review: comparative effectiveness of
medications to reduce risk for primary breast cancer) [36]
8 months 70 (KQ2,KQ3) 31 months
24 (KQ4)
16 (KQ5)
Comparative Effectiveness of Core Needle Biopsy and
Open Surgical Biopsy for Diagnosis of Breast Lesions;
Bruening (December 2009) [10]
September 2009 107 (KQ1-2) January 2008 to September 2011 19
(Systematic review: comparative effectiveness of
core-needle and open surgical biopsy to diagnose
breast lesions) [37]
3 months NA (KQ3) 24 months
Effectiveness of Recombinant Human Growth
Hormone (rhGH) in the Treatment of Patients with
Cystic Fibrosis; Phung (October 2010) [12]
April 2010 26(KQ1-2, KQ4, KQ6-7); 50
(KQ3); 3(KQ5)
January 2010 to August 2011 16
(Systematic review: recombinant human growth
hormone in the treatment of patients with cystic
fibrosis) [38]
6 months 16 months
Therapies for Children with Autism Spectrum
Disorders; Warren (April 2011) [13]
May 2010 159 January 2009 to October 2011 15
(Systematic review: a systematic review of early intensive
intervention for autism spectrum disorders) [39]
11 months 17 months
Comparative Effectiveness of Traumatic Brain Injury
and Depression;
June 2010 115 January 2010 to October 2011 29
Guillamondegui (April 2011) [15] 10 months 16 months
Pain Management Interventions for Hip Fracture;
Abou-Setta (May 2011) [14]
December 2010 98 January 2008 to November 2011 1
(Systematic review: comparative effectiveness of pain
management interventions for hip fracture: a
systematic review) [40]
5 months 11 months
Diagnosis and Treatment of Obstructive Sleep Apnea
in Adults; Balk (August 2011) [27]
September 2010 January 2010 to April 2012 35
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Table 2 Characteristics of 24 comparative effectiveness reviews (CERs) and their associated updating surveillance assessments (Continued)
44 (KQ1); 1 (KQ2); 2 (KQ3);
11 (KQ4); 173 (KQ5); 6 (KQ6);
18 (KQ7)
(Systematic review: auto-titrating versus fixed
continuous positive airway pressure for the treatment
of obstructive sleep apnea: a systematic review with
meta-analyses) [41]
11 months 19 months
Nonpharmacologic Interventions for Treatment-
Resistant Depression in Adults; Gaynes (September
2011) [30]
18 November 2010 64 January 2010 to March 2012 9
10 months 16 months
Attention Deficit Hyperactivity Disorder (ADHD):
Effectiveness of Treatment in At-Risk Preschoolers;
Long-term Effectiveness in All Ages; and Variability in
Prevalence, Diagnosis, and Treatment; Charach
(October 2011) [33]
31 May 2010 53 (KQ1); 76 (KQ2); NR (KQ3) January 2010 to June 2012 17
17 months 25 months
Effectiveness of Early Diagnosis, Prevention, and
Treatment of Clostridium difficile Infection; Butler
(December 2011) [29]
June 2010 and for KQ3
May 2011
13 (KQ1); 36 (KQ2); 13 (KQ3);
40 (KQ4)
January 2010 to June 2012 7
(Systematic review: comparative effectiveness of
Clostridium difficile treatments: a systematic review) [42]
7 to 18 months 24 months for KQ 1,2, 4
13 months for KQ3
Noncyclic Chronic Pelvic Pain Therapies for Women:
Comparative Effectiveness; Andrews (January 2012) [28]
May 2011 23 (KQ1); 7 (KQ2); 0 (KQ3); 17
(KQ4); 0 (KQ5)
May 2011 to July 2012 2
(Systematic review: systematic review of therapies for
noncyclic chronic pelvic pain in women) [43]
8 months 14 months
Chronic Kidney Disease Stages 1 to 3: Screening,
Monitoring, and Treatment;
January 2011 110 January 2011 to August 2012 20
Fink (January 2012) [31] 12 months 19 months
(Systematic review: screening for, monitoring, and
treatment of chronic kidney disease stages 1 to 3: a
systematic review for the US Preventive Services Task
Force and for an American College of Physicians
Clinical Practice Guideline) [44]
First and second generation antipsychotics for
children and young adults; Seida (February 2012) [32]
February 2011 81 January 2011 to August 2012 19
(Systematic review: antipsychotics for children and
young adults: a comparative effectiveness
review) [45]
12 months 18 months
Comparative Effectiveness of Management Strategies
for Renal Artery Stenosis: 2007 Update; Balk
(November 2007) [26]
23 April 2007 8 October 2006 to June 2012 7
7 months 62 months
Comparative Effectiveness of Radiofrequency Catheter
Ablation for Atrial Fibrillation; IP (July 2009) [18]
December 2008 120 June 2008 to September 2011 33
(Systematic review: comparative effectiveness of
radiofrequency catheter ablation for atrial fibrillation) [46]
7 months 35 months
Comparative Effectiveness of Lipid-Modifying Agents;
Sharma (September 2009) [17]
May 2009 101 November 2008 to October 2011 20
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Table 2 Characteristics of 24 comparative effectiveness reviews (CERs) and their associated updating surveillance assessments (Continued)
(Systematic review: comparative effectiveness and
harms of combination therapy and monotherapy for
dyslipidemia) [47]
4 months 29 months
Comparative Effectiveness of Angiotensin Converting
Enzyme Inhibitors or Angiotensin II Receptor Blockers
Added to Standard Medical Therapy for Treating
Stable Ischemic Heart Disease; Coleman (October
2009) [20]
February 2009 60 August 2008 to November 2011 12
(Systematic review: comparative effectiveness of
angiotensin-converting enzyme inhibitors or angiotensin
II-receptor blockers for ischemic heart disease) [48]
8 months 33 months
Comparative Effectiveness of In-Hospital Use of
Recombinant Factor VIIa for Off-Label Indications
versus Usual Care; Yank (May 2010) [16]
August 2009 74 February 2009 to January 2012 15
(Systematic review: benefits and harms of in-hospital use
of recombinant factor VIIa for off-label indications) [49]
9 months 29 months
Comparative effectiveness and safety of radiotherapy
treatments for head and neck cancer; Samson
(May 2010) [19]
September 2009 108 March 2009 to August 2011 7
8 months 23 months 15
Comparative Effectiveness of Nonoperative and
Operative Treatments for Rotator Cuff Tears; Sedia
(July 2010) [21]
September 2009 137 March 2009 to January 2012
(Systematic review: nonoperative and operative
treatments for rotator cuff tears) [50]
10 months 28 months
Comparative Effectiveness of Terbutaline Pump for
the Prevention of Preterm Birth; Gaudet (September
2011) [23]
April, 2011 14 October 2010 to March 2012 0
(Systematic review: effectiveness of Terbutaline Pump
for the Prevention of Preterm Birth. A Systematic
Review and Meta-Analysis) [51]
5 months 11 months
Self-Measured Blood Pressure Monitoring:
Comparative Effectiveness; Uhlig (January 2012) [24]
19 July 2011 48 (KQ1-2); 1( KQ5) January 2011 to August 2012 1
6 months 0 (KQ 3–4) 13 months
Hematopoietic Stem-Cell Transplantation in the
Pediatric Population; Ratko (February 2012) [25]
17 August 2011 251 February 2011 to September 2012 0
6 months 13 months
Abbreviations: CER Comparative Effectiveness Review, KQ key question, NR not reported.
Legend: Columns 1 to 3 present characteristics of CERs:
Column 1: title of the CER, first author’s last name, and title of the journal publication for the same CER.
Column 2: the date that last search was executed for the original CER (for instance, 17 August 2011 refers to the last literature search date carried out for CER), and the time lag between the last search date and the
release date of the original CER on the AHRQ website; for example, six months shows the CER was published/released on the AHRQ website six months after the last search date was executed for the CER.
Column 3: total number of studies included in the original CER; for example 251 means a total of 251 studied had met the inclusion criteria of the original CER and were reported in the original CER.
Column 4 presents: 1) time period that the surveillance assessment search has covered (for instance, February 2011 to September 2012 means the search was limited to the period between these dates), and 2) time
lag between the original CER search date and the surveillance assessment search date (for example, 13 months means the surveillance literature search was carried out 13 months after the last search date of the
original CER).
Column 5 reports the number of studies include in the surveillance assessment; for instance, (15) shows that a total of 15 studies deem eligible and were reported in the surveillance assessment.
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The total number of conclusions per report that required
assessment, a reflection of the number of subquestions,
ranged from 7 to 86 (the median number was 23). The
median number of included studies in the original SRs
was 104 (IQR: 71 to 124). The median number of newly
identified studies deemed relevant for inclusion in the SRs
was 15 (range: 0 to 35).
The number of experts initially contacted across the
24 SRs ranged from 4 [17] to 17 [30]. The response rates
ranged from 20% (2/10) to 100% (6/6) with a median of
35%.
Of the 24 SRs, nine [37%] were considered up-to-date
as defined by agreement that all conclusions for all key
questions were still up-to-date [12,15,21,23-25,28,30,31].
For the remaining 15 (63%) SRs [10,11,13,14,16-20,22,26,
27,29,32,33], at least one conclusion was rated as ‘prob-
ably/possibly out-of-date’ or ‘out-of-date.’ For four (17%)
SRs [10,19,20,22], all conclusions within at least one key
question were rated as ‘probably/possibly out-of-date’ or
‘out-of-date’ (see Table 3).
Most SRs were assigned a low priority for updating: two
out of 24 SRs (8%) [17,22] were assigned a ‘high’ priority
for updating; five out of 24 (21%) [10,11,19,26,27] were
assigned a medium priority, and the remaining 17 (71%)
were assigned a low priority [12-16,18,20,21,23-25,28-33]
(see Table 3).
Ten SR topics underwent a second surveillance assess-
ment. For those SRs, we contacted only those experts
who had responded in the first round. Across these ten
SRs, 39 experts were contacted, and 27 responded, with
response rates ranging from 40% to 100%. Median re-
sponse rate was 71%, double the 35% median response
rates across all topics on the first round. Across these
ten SRs that underwent a second surveillance assess-
ment at about six months from the end of the prior as-
sessment, there were 265 conclusions contained within
53 key questions. Of these, eight conclusions changed
between the first and second surveillance: seven conclu-
sions changed from ‘up-to-date’ to ‘possibly out-of-date’,
and one conclusion changed from ‘possibly out-of-date’
to ‘probably out-of-date’. One of the ten SRs changed
priority for updating from ‘low’ to ‘medium’.
Factors associated with priority decisions
We assessed whether the length of time that had
elapsed between the search conducted for the original
report and the update surveillance search (search time
lapse, STL) was associated with priority status for up-
dating. Seven SRs were released prior to January 2010
[10,11,17,18,20,22,26] (that is, more than 18 months be-
fore the start of the Surveillance Program); of these
seven, two were the SRs judged as being ‘high’ priority
for updating, three were judged as being ‘medium’priority, and two were judged as being ‘low’ priority for
updating. Of the remaining 17 SRs, released after January
2010, only two were judged as being ‘medium’ priority for
updating and the rest were low priority. All SRs released
within the year prior to the start of the Surveillance
Program (between June 2010 and June 2011) were judged
as being ‘low’ priority. Figure 2a and b present the updating
priority decisions for the 24 SRs by the time elapsed since
the search date in the original review (2a) and the number
of new relevant articles identified during the surveillance
process (2b). While more SRs were classified as medium or
high priority for updating as both the STL and the number
of new relevant articles increased, there was substantial
overlap, and no threshold existed for either time or number
of articles that could accurately predict classification of
SRs into different categories.
The possible role of safety alerts
We identified applicable safety alerts for 9 of the 24 SRs
assessed. FDA provided alerts for all nine of those SRs
[12,13,15,17,20,27,28,31,33]; MHRA and Health Canada
were the sources of alerts for only one SR [33]. None of
the agents, devices, or procedures evaluated in the 24
SRs for which we performed the surveillance assess-
ments had an FDA black box warning (the strongest
FDA warning, indicating a significant risk of serious or
even life-threatening adverse effect) issued during our
assessment period. In only one case was the updating
priority of a SR influenced by a safety alert [27].
Discussion
Our results indicate that a small proportion of AHRQ-
supported SRs may need updating within one to two
years of the date of their last search. Of the 24 SRs
assessed between June 2011 and November 2012, 17
(71%) were classified as having low priority for updating,
and five SRs (21%) had medium priority for updating.
Only two SRs (8%) were deemed to have high priority.
Greater elapsed time from the end date of the ori-
ginal search and a larger number of new relevant
studies were both associated with a higher priority for
updating, but no thresholds were identified that could
perfectly classify SRs into priority categories. This
finding suggests that expert opinion will be a neces-
sary component of an efficient system of searching
for signals for updating.
Several of the SRs were classified as low priority for
updating despite having a large number of newly identi-
fied potentially relevant studies. One explanation for this
finding is that, in general, many of these new studies had
small sample sizes or few primary outcomes and the re-
sults were consistent with those of the original SRs, thus
not justifying updating those existing SRs. Conversely,
the presence of a single new study with many outcome
Table 3 Currency of individual conclusions within each key questions of the of 24 comparative effectiveness reviews (CERs) and their priority status for
updating (high, medium, and low) based on the updating surveillance assessments
CER title author name (publication date) Number of conclusions within the key questions in Updating
priority for the CER
CER by updating status (low, medium,
and high)
KQ# # Conclusions
Up-to-date
KQ# # Conclusions
Possibly
out-of-date
KQ# # Conclusions
Probably
out-of-date
KQ# # Conclusions
Out-of-date
Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer;
Wilt (February 2008) [22]
1 11/15 1 2/15 1 2/15 High
2 1/1
3 3/3
4 1/3 4 2/3
Comparative Effectiveness of Medications to Reduce Risk of Primary Breast Cancer in
Women; Nelson (September 2009) [11]
1 4/6 1 2/6 Medium
2 6/7 2 1/7
3 4/5 3 1/5
4- 5 9/9
Comparative Effectiveness of Core Needle Biopsy and Open Surgical Biopsy for
Diagnosis of Breast Lesions; Bruening (December, 2009) [10]
1 10/16 1a 4/16 1 2/16 Medium
2 3/4 2 1/4
3 1/2 3 1/2
Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of
Patients with Cystic Fibrosis; Phung (October 2010) [12]
1-7 40/40 Low
Therapies for Children with Autism Spectrum Disorders; Warren (April 2011) [13] 1 10/14 1 4/14 Low
2 2/3 2 1/3
3-7 6/6
Comparative Effectiveness of Traumatic Brain Injury and Depression; Guillamondegui
(April 2011) [15]
1-6 15/15 Low
Pain Management Interventions for Hip Fracture; Abou-Setta (May 2011) [14] 1 7/8 1 1/8 Low
Diagnosis and Treatment of Obstructive Sleep Apnea in Adults; Balk (August 2011) [27] 1 3/4 1 1/4 Medium
2 1/1
3 1/1
4 1/1
5 14/15 5 1/15
6 1/1
7 1/1
1a 1/1 Low
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Table 3 Currency of individual conclusions within each key questions of the of 24 comparative effectiveness reviews (CERs) and their priority status for
updating (high, medium, and low) based on the updating surveillance assessments (Continued)
Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults;
Gaynes (September 2011) [30]
1b 1/1
2 1/1
3 1/1
4 1/1
5 1/1
6 1/1
Attention Deficit Hyperactivity Disorder (ADHD): Effectiveness of Treatment in At-Risk
Preschoolers; Long-term Effectiveness in all Ages; and Variability in Prevalence,
Diagnosis, and Treatment; Charach (October 2011) [33]
1 2/3 1 1/3 Low
2 5/6 2 1/6
3 10/12 3 2/12
Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile
Infection; Butler (December 2011) [29]
1 2/3 1 1/3 Low
2 6/8 2 2/8
3 6/7 3 1/7
4 4/5 4 1/5
Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness;
Andrews (January 2012) [28]
1 5/5 Low
2 6/6
3 1/1
4 6/6
5 1/1
all 2/2
Chronic Kidney Disease Stages 1 to 3: Screening, Monitoring, and Treatment; Fink
(January 2012) [31]
1-6 25/25 Low
First and Second Generation Antipsychotics for Children and Young Adults; Seida
(February 2012) [32]
1 4/7 1 2/7 1 1/7 Low
2 3/3
3 4/4
4 1/1
Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: 2007
Update; Balk (November 2007) [26]
1 7/15 1 8/15 Medium
2 2/3 2 1/3
3 4/4
Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation;
IP (July 2009) [18]
1 4/4 Low
2 3/5 2 2/5
3 3/4 3 1/4
4 6/6
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Table 3 Currency of individual conclusions within each key questions of the of 24 comparative effectiveness reviews (CERs) and their priority status for
updating (high, medium, and low) based on the updating surveillance assessments (Continued)
Comparative Effectiveness of Lipid-Modifying Agents; Sharma (September 2009) [17] 1 3/13 1 10/13 High
2 34/48 2 14/48
3 9/25 3 16/25
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or
Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating
Stable Ischemic Heart Disease; Coleman (October 2009) [20]
1 6/7 1 1/7 Low
2-6 28/28
7 4/4
Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for
Off-Label Indications versus Usual Care; Yank (May 2010) [16]
2 2/3 2 1/3 Low
3a 7/9 3a 2/9
3b 3/4 3b 1/4
4a 1/2 4a 1/2
4b-c 9/9
Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and
Neck Cancer; Samson (May 2010) [19]
1 2/3 1 1/3 Medium
2 1/2 2 1/2
3 1/1
4 3/3
Comparative Effectiveness of Nonoperative and Operative Treatments for Rotator
Cuff Tears; Sedia (July 2010) [21]
1- 6 18/18 Low
Comparative Effectiveness of Terbutaline Pump for the Prevention of Preterm Birth;
Gaudet (September 2011) [23]
1-6 37/37 Low
Self-Measured Blood Pressure Monitoring: Comparative Effectiveness;
Uhlig (January 2012) [24]
1 8/8 Low
2 4/4
3 4/4
4 2/2
5 2/2
Hematopoietic Stem-Cell Transplantation in the Pediatric Population;
Ratko (February 2012) [25]
1 3/3 Low
2 3/3
3 5/5
4 5/5
5 5/5
6 5/5
Abbreviations: CER Comparative Effectiveness Review, KQ key question
Legend: Column 1 reports the title and first author of the CERs assessed.
Column 2 reports the currency of each conclusion within each key questions of each CER. For example; CER [22] had a total of four key questions. Key question 1 had a total of 15 conclusions, of which 11 were
assessed to be up-to-date, 2 possibly out-of-date and 2 out-of-date based on the surveillance assessment. Column 3 demonstrates the final conclusion (updating priority status) of surveillance assessment for individual
CER, for example, if a CER is assessed as high priority for updating, the column shows ‘high’. The symbol # refers to “number” inside the table.
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Figure 2 The process of surveillance assessment for a Systematic Review. (a) Time elapsed since the search date in the original review.
Green color: low priority for updating; Yellow color: medium priority for updating; red color: high priority for updating. (b) Number of new
relevant articles identified. Green color: low priority for updating; Yellow color: medium priority for updating; red color: high priority for updating.
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http://www.systematicreviewsjournal.com/content/2/1/104events can be a sufficient signal of the need for a high
priority update, such as the publication of the Prostate
Cancer Intervention Versus Observation Trial (PIVOT)
[52] and the SR on therapies for clinically localized pros-
tate cancer [22].
A recent study that examined factors that predicted 69
decisions on whether to update 41 reviews of drug ef-
fectiveness found that the number of relevant new stud-
ies was a significant predictor of a decision to update a
review (OR 1.06 for each new trial) [6]. This study,
conducted for the Drug Effectiveness Review Project
(DERP), was designed to examine the surveillance
process implemented in 2006 to replace what had been a
policy of mandatory annual updates. The DERP process
is qualitatively similar to our surveillance method, inthat it uses limited literature searches, information from
FDA and Health Canada, and expert input. The study also
found that identification of a new drug significantly in-
creased the likelihood of an update (OR = 5.71) and that
reviews of psychiatric drugs were always recommended
for an update. The authors did not report whether there
were thresholds of articles or time that perfectly predicted
decisions for updating. A major difference between that
study and ours, aside from our broader focus on all types
of clinical interventions, is that the decision to update a
DERP report rests with a panel of participants comprising
physicians and representatives of the state Medicaid agen-
cies and the Canadian Agency for Drug Technology and
Health, for whom the appearance of a new drug requires
them to make policy decision.
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The implementation of the surveillance assessment pro-
gram to determine the currency of published AHRQ SRs
has presented a number of challenges. These challenges
included differences across reports in the ways conclu-
sions were presented, the responsiveness of report staff
and experts, and delays in the release of the original re-
ports themselves combined with differences in the
length of time between release and surveillance.Inconsistency in presentation of conclusions
Not all SRs presented their KQs and the corresponding
conclusions in the executive summary in a similar man-
ner (that is, the degree of detail, format, or level of
summarization may have varied). For example, in some
SRs, conclusions were, by necessity, stratified by subpop-
ulation, intervention, outcome, or other study character-
istics, resulting in multiple conclusions for a single
question. In some SRs, the executive summaries failed to
present sufficient detail to enable reviewers to extract at
least one specific, clearly formulated conclusion for each
key question; therefore, the reviewers had to probe the
entire text of the SR report. Conversely, some executive
summaries simply reproduced the results from the re-
port text without drawing any conclusions, leaving the
experts to whom we sent the information to draw their
own conclusions. Some conclusions were not readily
amenable to updating, for example, conclusions regard-
ing the prevalence of certain risk factors in specific
populations.Responsiveness of report staff and experts
Conducting the surveillance on schedule required that the
project leads for the original reports and the experts they
recommended we contact respond in a timely manner.
However, project leads and experts varied widely in their
responsiveness to our requests. In addition, response rates
were low in the first surveillance. However, it is unclear
what this low response means, since the sample is not
intended to be a random sample of some larger popula-
tion. In the second round of surveillance, the response
rate improved considerably, suggesting that over time, the
surveillance process will become more efficient.Delays in release of some reports
In several cases, surveillance was delayed because a re-
port was not released on schedule. The primary impact
of such delays was on our staff ’s ability to plan their
work schedules, as they would have reserved time for
these reports and would need to find other surveillance
work or work on our own evidence reviews when a re-
port expected for surveillance failed to materialize.Limitations
One limitation of the surveillance system is that it requires
subjective global judgments. The assessment of currency
and validity of conclusions for each key question in a SR
was based on the totality of information compiled through
multiple sources such as the qualitative/quantitative sig-
nals, expert opinion, and safety alerts. Although we used
operational and standardized definitions throughout the
process to promote consistency in the assessments, the
overall judgment must necessarily be subjective in charac-
terizing individual conclusions. However, since neither the
STL nor the number of new relevant studies can classify
SRs perfectly as low, medium, or high priority status for
updating, this subjective human assessment is going to be
needed in an efficient surveillance system. Future work
should seek to make these judgments as reliable as pos-
sible across raters. The strength of evidence should be in-
vestigated in future work.
A second limitation is that we present data for only 34
surveillance assessments on 24 SRs. However, only two
published evaluations have included more assessments than
ours. A study by Shojania and colleagues assessed 100 sys-
tematic reviews to determine how quickly they go out-of-
date, but this study limited its sample to meta-analyses that
produced a summary estimate of outcome, and then fur-
ther limited the analysis to only one outcome per study [7].
The DERP study reported the results of surveillance on 41
of their reports [6], but these reports assessed only drugs,
and the decisions about updating were made by stake-
holders for whom the approval of a new drug was highly
relevant to policy decision-making. Our study, by contrast,
assesses a broad array of health care interventions, and con-
sidered changes in evidence that might lead to changes in
practice as the criterion for a signal for updating.
In sum, we found that only a small proportion of AHRQ-
sponsored systematic reviews triggered signals for updating
within one or two years of the date of their last search, and
that neither the elapsed time since the original search nor
the number of new articles could perfectly predict which SRs
may be in need of updating. Our experience also provided
some evidence into what might be the optimal time for a
first assessment and subsequent surveillance assessments.
Among the 24 SRs released within the first 18 months of
surveillance, only two were classified as high priority, five
were classified as medium, and the rest were classified as
‘low’ priority for updating (and a number of these reports
had been released up to four years prior to the start of the
surveillance). Furthermore, there were few changes in con-
clusions about updating in a second round of surveillance
timed to start six months after the completion of the first
round. These results suggest to us that a one-year time
period between the release of a report and its first and subse-
quent surveillance assessments may be more efficient than
the six-month time frame chosen for this application.
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By undertaking periodic evaluation of 24 topically di-
verse SRs commissioned by a leading organization, we
established the feasibility of a surveillance system to
monitor SR currency for a wide range of therapeutic in-
terventions. About 70% of reviews were determined to
have a low priority for updating. Evidence suggests that
the optimal interval for surveillance is yearly.
For future research, we recommend: 1) modifying and
testing the current surveillance methodology to encompass
reviews of diagnostic and prognostic methods; 2) validating
the surveillance methods against the gold standard of ac-
tual review updates in a blinded fashion; and 3) identifying
predictors of a review being out-of-date; for example, re-
view quality or the strength of evidence for each individual
conclusion; and 4) assessment of the relationship between
the quality or strength of evidence and signal detection.
Additional file
Additional file 1: Decision rules for determining updating status of
a CER conclusion.
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